Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Replication-Competent Adenovirus-Mediated Double Suicide Gene Therapy With Stereotactic Radiosurgery in Patients With Recurrent or Progressive High Grade Astrocytomas

NCT05686798 is registered in ClinicalTrials.gov with Henry Ford Health System as lead sponsor.

NCT NCT05686798
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05686798 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Replication-Competent Adenovirus-Mediated Double Suicide Gene Therapy With Stereotactic Radiosurgery in Patients With Recurrent or Progressive High Grade Astrocytomas
Lead sponsor
Henry Ford Health System
Phase
Phase 1
Overall status
Recruiting
Start date
November 29, 2022
Completion date
December 31, 2027
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

astrocytoma, brain cancer, brain tumor, gbm, glioblastoma, glioblastoma multiforme, glioma, malignant astrocytoma, malignant glioma of brain